Time trends of overall survival among metastatic breast cancer patients in the real-life ESME cohort
Time trends of overall survival among metastatic breast cancer patients in the real-life ESME cohort
复制标题
DOI：
10.1016/j.ejca.2018.03.015
复制
发表时间：
2018-06-01
影响因子：
8.4
通讯作者：
Delaloge, Suzette
中科院分区：
文献类型：
--
作者：
Gobbini, Elisa;Ezzalfani, Monia;Delaloge, Suzette
目的：对转移性乳腺癌(MBC)患者总体生存(OS)趋势的真实分析可能有助于确定医疗需求和评估公共卫生投资的影响。方法：ESME-MBC(NCT03275311)是一个法国、国家、多中心、观察性队列，包括16,702例新诊断的MBC患者(2008年1月1日至2014年12月31日)。在16,680名符合条件的患者中，15,085人拥有完整的免疫组织化学数据，从而可以将其分为激素受体阳性和HER2阴性(HR+/HER2-，N=9907)、HER2阳性(HER2+，N=2861)或三重阴性(HR-/HER2-，N=2317)亚群。结果：整个队列的中位OS为37.22个月(95%可信区间，36.3-38.04)。诊断年份是OS的独立预测因子(危险比0.98[95%CI，0.97-1.00]，P=.01)以及年龄、亚型、无病间隔、内脏转移和累及的器官数目。HR+/HER2-、HER2+和HR-/HER2-亚组的中位OS分别为42.12(95%CI，40.90~43.10)、44.91(95%CI，42.51~47.90)和14.52(95%CI，13.70~15.24)个月。诊断年限是HER2+亚群OS的独立预测因素(危险比0.91[95%CI，0.88-0.94]，P
Aim: Real-life analysis of overall survival (OS) trends among metastatic breast cancer (MBC) patients may help define medical needs and evaluate the impact of public health investments. The present study aimed to evaluate the independent impact of the year of MBC diagnosis on OS in the Epidemio-Strategy-Medical-Economical (ESME)-MBC cohort.Methods: ESME-MBC (NCT03275311) is a French, national, multicentre, observational cohort including 16,702 consecutive newly diagnosed MBC patients (01 January 2008-31 December 2014). Of 16,680 eligible patients, 15,085 had full immunohistochemistry data, allowing classification as hormone receptor-positive and HER2-negative (HR+/HER2-, N=9907), HER2-positive (HER2+, N=2861) or triple-negative (HR-/HER2-, N=2317) subcohorts. Multivariate analyses of OS were conducted among the full ESME cohort and subcohorts.Results: Median OS of the whole cohort was 37.22 months (95% confidence interval [CI], 36.3-38.04). Year of diagnosis was an independent predictor of OS (hazard ratio 0.98 [95% CI, 0.97-1.00], P=.01) together with age, subtype, disease-free interval, visceral metastases and number of organs involved. Median OS of HR+/HER2-, HER2+ and HR-/HER2- subcohorts was, respectively, 42.12 (95% CI, 40.90-43.10), 44.91 (95% CI, 42.51-47.90) and 14.52 (95% CI, 13.70-15.24) months. Year of diagnosis was a strong independent predictor of OS in HER2+ subcohort (hazard ratio 0.91 [95% CI, 0.88-0.94], P